Darier Laboratories is a vertically integrated specialty pharmaceutical company that develops, manufactures, markets, and sells therapies and technologies exclusively in dermatology.
Profile
Darier Laboratories is a vertically integrated specialty
pharmaceutical company that develops, manufactures and
commercializes dermatrology products and solutions.
Darier has unique strengths in go to market abilities,
product-enhancement and development, clinical development,
manufacturing, and regulatory affairs, which make the
company a proven partner of choice for early to late stage
compounds and novel branded prescription pharmaceutical
products and technologies.
Darier Laboratories is the market leader in Dermatology in
Mexico, with
marketing and go-to-market resources in Latin America added
to a development and production unit (GMP accreditation) in
Mexico.
Darier's product offer includes a wide range of dermatological
products, from prescription to Dermoceuticals. The line
includes Acne, Atopical Dermatitis, Sunscreens and Skin
Cancer. Thanks to an exclusive niche strategy from its
creation, Darier has been consistently performing above the
average and occupies today the lead with more than 10%
market share (IMS) in México. The strength of Darier lies on
the best combination of high product quality and innovation
as well as privileged relationships with Dermatologists and
Pediatricians built up over 24 years.
Darier operates its own factory that runs under GMP
excellence standards. Besides a versatile plant, it recently
inaugurated (2005) a modern steroids plant. It
also performs toll and contract manufacturing for third
parties at highly competitive cost/quality standards. More
than 35 Free Trade unilateral and multilateral Agreements
(NAFTA, EU, etc.) confer to Mexico a unique position in the
International Trade.
Partnering strategy/interests
Darier is actively seeking collaborations, strategic
alliances and business development opportunities including:
1) New product developments in dermatology, from
finished products/line extensions to New Chemical Entities
(early to late stages), including but not limited to Acne,
Atopic Dermatitis and Skin Cancer protection. This can
happen through In-Licensing, co-development, acquisitions.
Patents preferred.
2) New Delivery Systems and innovatie topical and oral
technologies.
3) Out-Licensing and Exports: existing product lines of
Darier (pharma and dermo/cosmeceuticals) as well as
patented New Chemicals Entities in Dermatology available
outside of México
4) Toll and Contract Manufacturing (including but not
limited to semi-solids, solids and steroids).